WASHINGTON — Drug and device companies with manufacturing operations in Puerto Rico have told the American public that their plants are getting up and running again, but that does “not reveal the true scope of the challenge that we are facing,” Food and Drug Administration Commissioner Scott Gottlieb said in prepared congressional testimony made available Monday.

“We have surveyed firms and can anecdotally relate that reports of manufacturing running below 50 percent are common, with many firms operating around 20 percent capacity, and some even less,” Gottlieb’s remarks read. “We have found no firm operating above 70 percent of their normal operation.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy